Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

NVS – Novartis AG

Novartis AG
NVS
$115.30
Name : Novartis AG
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $223,994,478,592.00
EPSttm : 6.86
finviz dynamic chart for NVS
Novartis AG
$115.30
1.37%
$1.56

Float Short %

0.22

Margin Of Safety %

1

Put/Call OI Ratio

1.2

EPS Next Q Diff

-0.4

EPS Last/This Y

3.08

EPS This/Next Y

0.28

Price

115.3

Target Price

125.34

Analyst Recom

2.92

Performance Q

3.57

Relative Volume

1.18

Beta

0.62

Ticker: NVS




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-04NVS121.91.222.7559517
2025-07-07NVS122.111.241.1659912
2025-07-08NVS121.681.243.2460109
2025-07-09NVS122.941.252.5460810
2025-07-10NVS123.711.270.3061327
2025-07-11NVS120.961.250.6161836
2025-07-14NVS121.071.240.1362595
2025-07-15NVS119.661.242.6362691
2025-07-16NVS118.481.261.5863658
2025-07-17NVS114.521.291.1664716
2025-07-18NVS114.21.211.4164472
2025-07-21NVS114.21.420.3247098
2025-07-22NVS116.891.340.1147781
2025-07-23NVS1181.230.6949801
2025-07-24NVS117.421.230.1749948
2025-07-25NVS117.681.220.0650120
2025-07-28NVS116.21.200.7250514
2025-07-29NVS117.191.191.0351602
2025-07-30NVS116.641.193.6951823
2025-07-31NVS113.741.201.0951955
2025-08-01NVS115.071.201.8852251
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-04NVS121.9020.52916.28.83
2025-07-07NVS122.1620.53222.18.83
2025-07-08NVS121.6820.53068.78.83
2025-07-09NVS122.9420.53293.08.83
2025-07-10NVS123.7320.53404.88.83
2025-07-11NVS121.0220.53018.38.83
2025-07-14NVS121.0920.53284.58.83
2025-07-15NVS119.6720.53045.08.83
2025-07-16NVS118.4320.52955.88.83
2025-07-17NVS114.5220.52627.88.83
2025-07-18NVS114.2120.53128.38.83
2025-07-21NVS114.1520.52623.28.83
2025-07-22NVS116.8820.53063.38.83
2025-07-23NVS117.9720.53044.78.83
2025-07-24NVS117.4611.42686.19.00
2025-07-25NVS117.7011.42828.19.00
2025-07-28NVS116.1511.42572.89.00
2025-07-29NVS117.2211.42651.49.00
2025-07-30NVS116.6311.42478.79.00
2025-07-31NVS113.7411.42048.69.00
2025-08-01NVS115.3011.42429.19.00
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-04NVS00.630.20
2025-07-07NVS00.500.20
2025-07-08NVS00.500.20
2025-07-09NVS00.500.20
2025-07-10NVS00.500.20
2025-07-11NVS00.500.21
2025-07-14NVS01.060.21
2025-07-15NVS01.060.21
2025-07-16NVS01.060.21
2025-07-17NVS01.060.21
2025-07-18NVS01.060.21
2025-07-21NVS01.150.21
2025-07-22NVS01.150.21
2025-07-23NVS01.150.21
2025-07-24NVS01.150.21
2025-07-25NVS01.150.22
2025-07-28NVS00.830.22
2025-07-29NVS00.830.22
2025-07-30NVS00.830.22
2025-07-31NVS00.830.22
2025-08-01NVS00.830.22
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

2.42

Avg. EPS Est. Current Quarter

2.29

Avg. EPS Est. Next Quarter

2.02

Insider Transactions

Institutional Transactions

0.83

Beta

0.62

Average Sales Estimate Current Quarter

13689

Average Sales Estimate Next Quarter

13581

Fair Value

115.9

Quality Score

97

Growth Score

70

Sentiment Score

77

Actual DrawDown %

7.6

Max Drawdown 5-Year %

-20.4

Target Price

125.34

P/E

16.7

Forward P/E

12.49

PEG

2.12

P/S

4.09

P/B

5.32

P/Free Cash Flow

11.26

EPS

6.91

Average EPS Est. Cur. Y​

9

EPS Next Y. (Est.)

9.28

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

25.65

Relative Volume

1.18

Return on Equity vs Sector %

8.8

Return on Equity vs Industry %

0.5

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.16

EBIT Estimation

2429.1
Novartis AG
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 75883
Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
stock quote shares NVS – Novartis AG Stock Price stock today
news today NVS – Novartis AG stock forecast ,stock prediction 2023 2024 2025
marketwatch NVS – Novartis AG yahoo finance google finance
stock history NVS – Novartis AG invest stock market
stock prices NVS premarket after hours
ticker NVS fair value insiders trading